Current Report Filing (8-k)
March 26 2015 - 4:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 20, 2015
Commission File Number: 000-50768
ACADIA
Pharmaceuticals Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
Delaware |
|
061376651 |
(State or other jurisdiction
of incorporation or organization) |
|
(IRS Employer
Identification No.) |
3611 Valley Centre Drive, Suite 300, San Diego, California 92130
(Address of principal executive offices)
858-558-2871
(Registrants Telephone number)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(d)
On March 20, 2015, our Board of Directors elected
Daniel Soland as a director to fill an existing vacancy. Mr. Soland received our standard compensation package for an outside director, including a stock option to purchase up to 15,000 shares of our common stock under our 2010 Equity Incentive
Plan, as amended. Information about our arrangements with our outside directors is included in our annual proxy statement, last filed on April 23, 2014, which includes the description of outside director compensation under Director
Compensation. Mr. Soland was not appointed to any committees at the time of his election.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: March 26, 2015 |
|
|
|
ACADIA Pharmaceuticals Inc. |
|
|
|
|
|
|
|
|
By: |
|
/s/ Glenn F. Baity |
|
|
|
|
Name: Glenn F. Baity |
|
|
|
|
Title: EVP, General Counsel & Secretary |
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024